Master in Bioinformatics, in silico drug design – Bioactive Molecules
Language(s) of instruction: English (100%)
Length of study: 2 years, full time
Partners:
- Université de Strasbourg
- Università degli Studi di Milano
- Universidade NOVA de Lisboa
- University of Ljubljana
- Bar-Ilan University
Course Location:
- Semester 1: Université Paris Cité, Paris, France
- Semester 2: Università degli Studi di Milano, Italy
- Semester 3: Université Paris Cité, France
- Semester 4: Location depending on the internship
Degrees awarded:
- Master Mention Bio-Informatique, Parcours : In Silico Drug Design – Bioactive Molecules, Université Paris Cité
- Erasmus Mundus label – Erasmus Mundus Joint Master’s program “ChEMoinformatics+”
Entry Requirements: Bachelor degree or international equivalent in a variety of subjects including chemistry, biochemistry, bioinformatics, biology, biotechnology, or the health sector
Language pre-requisites: B2 level of French and English
Course overview
The Master’s programme in In Silico Drug Design (ISDD) – Bioactive molecules, included in the Master’s degree of Bioinformatics (UFR of Life Sciences), was created in response to growing demand from both the pharmaceutical industry and academia to train students in this rapidly expanding field in France and Europe. Interdisciplinary in nature, the ISDD Master’s programme benefits from the collaboration of several universities, private companies, and international experts.
Oriented towards the modelling and design of small bioactive molecules, with a focus on chemoinformatics, molecular docking, artificial intelligence, and machine learning, the programme aims to provide comprehensive training in all aspects of drug discovery using in silico (computer-assisted) approaches.
Skills and competencies developed
- In silico research training in the discovery of bioactive compounds, with preparation for further doctoral studies.
- Skills development in rational exploration of chemical space to support the discovery of bioactive molecules, by combining artificial intelligence, molecular dynamics and virtual screening approaches for predicting the impact of xenobiotics on human health.
- Career readiness, enabling graduates to participate in or lead in silico drug design projects within pharmaceutical and medicinal chemistry companies, as well as in organizations developing chemicals or specialized software.